Related references
Note: Only part of the references are listed.A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy
Kathryn R. Wagner et al.
ANNALS OF NEUROLOGY (2008)
Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo
Yong-Fu Li et al.
BIOCONJUGATE CHEMISTRY (2008)
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice
Natee Jearawiriyapaisarn et al.
MOLECULAR THERAPY (2008)
Genetic and Chemical Modifiers of a CUG Toxicity Model in Drosophila
Amparo Garcia-Lopez et al.
PLOS ONE (2008)
Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors
Amanda M. Haidet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy
James P. Orengo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Local dystrophin restoration with antisense oligonucleotide PRO051
Judith C. van Deutekom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Design and implementation of cell-based assays to model human disease
Jeremy O. Jones et al.
ACS CHEMICAL BIOLOGY (2007)
A small molecule microarray platform to select RNA internal loop-ligand interactions
Jessica L. Childs-Disney et al.
ACS CHEMICAL BIOLOGY (2007)
Increased steady-state in levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation
N. Muge Kuyumcu-Martinez et al.
MOLECULAR CELL (2007)
Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy
Guey-Shin Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos
Paul A. Morcos
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs
Dana S. Mosher et al.
PLOS GENETICS (2007)
Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy
Eric L. Logigian et al.
MUSCLE & NERVE (2007)
Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1
T. M. Wheeler et al.
NEUROMUSCULAR DISORDERS (2007)
Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets
Jacelk Krol et al.
MOLECULAR CELL (2007)
Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy
John D. Lueck et al.
JOURNAL OF GENERAL PHYSIOLOGY (2007)
A bichromatic fluorescent reporter for cell-based screens of alternative splicing
James P. Orengo et al.
NUCLEIC ACIDS RESEARCH (2006)
RNA-dominant diseases
Robert J. Osborne et al.
HUMAN MOLECULAR GENETICS (2006)
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors
G. C. Minetti et al.
NATURE MEDICINE (2006)
Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy
Mani S. Mahadevan et al.
NATURE GENETICS (2006)
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy
Rahul N. Kanadia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy
Xiaoyan Lin et al.
HUMAN MOLECULAR GENETICS (2006)
Biologically active molecules that reduce polyglutamine aggregation and toxicity
Urvee A. Desai et al.
HUMAN MOLECULAR GENETICS (2006)
MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1
Maria de Haro et al.
HUMAN MOLECULAR GENETICS (2006)
DM2 intronic expansions:: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression
Jamie M. Margolis et al.
HUMAN MOLECULAR GENETICS (2006)
Myofibrillar protein synthesis in myostatin-deficient mice
S Welle et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology
J Alter et al.
NATURE MEDICINE (2006)
Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose
DR Clemmons et al.
GROWTH HORMONE & IGF RESEARCH (2005)
MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1
W Dansithong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles
QL Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Muscleblind proteins regulate alternative splicing
TH Ho et al.
EMBO JOURNAL (2004)
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
P Gregorevic et al.
NATURE MEDICINE (2004)
Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons
H Jiang et al.
HUMAN MOLECULAR GENETICS (2004)
Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1
M Tarnopolsky et al.
MUSCLE & NERVE (2004)
Brief report -: Myostatin mutation associated with gross muscle hypertrophy in a child
M Schuelke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Insulin receptor splicing alteration in myotonic dystrophy type 2
RS Savkur et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Regulation of muscle mass by myostatin
SJ Lee
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY (2004)
A muscleblind knockout model for myotonic dystrophy
RN Kanadia et al.
SCIENCE (2003)
Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts
MA Langlois et al.
MOLECULAR THERAPY (2003)
Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions
D Furling et al.
GENE THERAPY (2003)
Creatine monohydrate in DM2/PROMM - A double-blind placebo-controlled clinical study
C Schneider-Gold et al.
NEUROLOGY (2003)
Loss of myostatin attenuates severity of muscular dystrophy in mdx mice
KR Wagner et al.
ANNALS OF NEUROLOGY (2002)
Creatine monohydrate in myotonic dystrophy -: A double-blind, placebo-controlled clinical study
MC Walter et al.
JOURNAL OF NEUROLOGY (2002)
Functional improvement of dystrophic muscle by myostatin blockade
S Bogdanovich et al.
NATURE (2002)
Expanded CUG repeats trigger aberrant splicing of CIC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy
A Mankodi et al.
MOLECULAR CELL (2002)
Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing
N Charlet-B et al.
MOLECULAR CELL (2002)
Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: A double-blind, placebo-controlled pilot study
S Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice
ER Barton et al.
JOURNAL OF CELL BIOLOGY (2002)
Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy
RS Savkur et al.
NATURE GENETICS (2001)
Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9
CL Liquori et al.
SCIENCE (2001)
Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle
A Musarò et al.
NATURE GENETICS (2001)
Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy
JW Miller et al.
EMBO JOURNAL (2000)
Share Paper
